α-Amylase- and Redox-Responsive Nanoparticles for Tumor-Targeted Drug Delivery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Paclitaxel (PTX) is a potent anticancer drug, but its clinical application is hindered by poor solubility and side effects.
• Current PTX formulations face challenges in effective tumor targeting and delivery.

Purpose of the Study:

• To develop novel α-amylase- and redox-responsive nanoparticles for targeted paclitaxel delivery.
• To overcome the limitations of conventional paclitaxel formulations for improved cancer chemotherapy.

Main Methods:

• Synthesized HES-SS-PTX conjugates using redox-sensitive disulfide bonds.
• Characterized nanoparticle formation and stability using DLS, TEM, and AFM.
• Evaluated nanoparticle performance through pharmacokinetic studies, in vivo imaging, and cytotoxicity assays.

Main Results:

• HES-SS-PTX nanoparticles demonstrated stability and responsiveness to α-amylase and reductive stimuli.
• Pharmacokinetic studies showed a longer half-life and enhanced tumor accumulation compared to Taxol.
• In vivo studies revealed improved antitumor efficacy and reduced toxicity in 4T1 tumor-bearing mice.

Conclusions:

• HES-based nanoparticles offer a promising platform for targeted paclitaxel delivery in cancer therapy.
• The α-amylase and redox responsiveness of these nanoparticles enhance drug release and therapeutic outcomes.
• These findings suggest significant clinical translation potential for advanced cancer chemotherapy.